CAMBRIDGE, Mass., Nov. 26, 2018 — Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, today announced that Thomas Schuetz, M.D., Ph.D., co-founder and chief executive officer, will present a corporate update at the 30th Annual Piper Jaffray Healthcare Conference which takes place November 27-29 in New York, NY.
The presentation details are:
Date: Tuesday, November 27th
Time: 1:50PM – 2:10PM
Location: Harlem Track – Kennedy 2, 4th Floor at the Lotte New York Palace
Dr. Schuetz will present the company’s proprietary antibody development platform, which combines state-of-the-art antibody discovery with protein engineering technologies to generate a wide array of molecules targeting the broadest epitopic diversity for every target. He will also share the most recent data on the company’s lead candidate, CTX-471, a fully human monoclonal antibody that induces remodeling of the tumor microenvironment and leads to immune-mediated destruction of solid tumors, as well as additional pipeline candidates. To date, the company’s integrated R&D approach has generated therapeutic candidates for more than 30 targets in cancer, inflammation and autoimmune disease. More than 15 of them are now advancing through preclinical development.
About Compass Therapeutics
Compass Therapeutics has multiple antibody, antibody combination and bispecific programs advancing through preclinical development, targeting multiple pathways of significance for the immune system. The company’s offices and labs are based in Kendall Square in Cambridge, Mass. Compass currently has approximately 80 full-time employees.
Ten Bridge Communications